BPC-157 + TB-500 blend reconstitution protocol

This protocol describes the reconstitution and storage of the lyophilized BPC-157 + TB-500 blend in standard research workflows. The two compounds are co-formulated because they target complementary tissue-repair pathways and are commonly studied together in regenerative-research models. Values below reflect published handling literature; study design is the responsibility of the qualified investigator.

At a glance

Parameter	Value
Recommended diluent	Bacteriostatic Water (USP, 0.9% benzyl alcohol)
Recommended volume (10 mg combined: 5 mg BPC-157 + 5 mg TB-500)	2.0 mL
Final concentration	BPC-157: 2.5 mg/mL · TB-500: 2.5 mg/mL (5 mg/mL combined)
Stability — lyophilized	≥24 months at -20 °C, light-protected, sealed
Stability — reconstituted	30 days at 2–8 °C in original vial
Routes studied	Subcutaneous, intraperitoneal (rodent models)

Procedure

1. Equilibrate the vial to room temperature.
2. Sterile prep: wipe stopper with isopropyl. Use sterile syringe and needle.
3. Inject diluent slowly along the inner wall. Both compounds dissolve readily.
4. Swirl gently. Do not shake. Dissolution completes within 30–60 seconds.
5. Verify: solution should be clear and colorless. Mild iridescence is normal due to the acetate counterion of BPC-157.

Why the two compounds are blended

BPC-157 and TB-500 (also called Thymosin Beta-4) are both studied for tissue-repair effects but operate through largely distinct mechanisms — combining them in research models is intended to access both pathways:

• BPC-157 influences angiogenesis (VEGF expression), nitric-oxide signaling, and fibroblast activity. Most replicated effects: tendon and ligament healing, gut mucosal protection, wound repair.
• TB-500 (or specifically its active fragment, AcSDKP) influences actin sequestration and cell migration. Most replicated effects: cardiac and skeletal muscle repair, dermal wound healing, anti-fibrotic activity.

The two pathways are partially overlapping (both affect angiogenesis and inflammation) but qualitatively different in their dominant cellular targets. Co-administering them in research models is intended to combine accelerated tissue repair (BPC-157) with improved cell migration into the repair site (TB-500). The combination is the most-studied protocol in BPC-157/TB-500 regenerative research.

Compound notes

BPC-157 is a 15-residue pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) typically supplied as the acetate salt. TB-500 in research compound catalogs is usually the synthetic full-length Thymosin Beta-4 sequence rather than the AcSDKP fragment alone — Merit's blend uses full-length Tβ4. Both compounds are robust in solution at the concentrations and pH used here; neither has unusual stability considerations beyond the standard freeze-thaw avoidance.

Storage

Reconstituted blend is stable for approximately 30 days at 2–8 °C. For longer storage, aliquot into sterile single-use tubes and freeze at -20 °C or colder. Lyophilized stability is ≥24 months at -20 °C light-protected.

Notes

This protocol describes reconstitution parameters from published handling literature. It is not a recommendation for any specific research protocol or design. For research use only. Not for human or veterinary use.

References

1. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 2011;110:774–780. PMID: 21030672
2. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res 2007;84:663–669. PMID: 17320071